Reading the evidence

What Eye Trials Actually Measure, And Why It Is Rarely The Eye Chart

A very common disappointment with eye supplements goes like this: three months in, the reading on the letter chart has not changed, so nothing happened. The letter chart is the wrong instrument for the question, and almost no trial in this field uses it as a primary outcome. This article explains what they do measure instead, and what that means for judging a capsule at home.

Reading the evidence · Visivra Team at Govisivra · physician review: Dr. Preston Sullivan, MD · last revised September 30, 2026

What the letter chart is actually for

Visual acuity is the measurement everybody knows: read down the chart until the letters get too small. It answers one question, which is how fine a detail you can resolve when the contrast is maximal, black letters on white.

That number is set mostly by the optics of your eye. The shape of the cornea, the state of the lens, the length of the eyeball, and whether you are wearing the right correction. A nutrient does not change any of those.

So a carotenoid supplement moving an acuity reading would be surprising, and it is not what these trials set out to find. Somebody who buys an eye supplement and then judges it on the chart has chosen an instrument that was never going to respond.

The exception worth naming

Acuity does change in disease, which is why it is a secondary outcome in the disease trials. AREDS2 recorded it. But it recorded it in people who already had macular degeneration and were being watched for progression, which is a different situation entirely from a healthy adult wondering whether a capsule is working.

Contrast sensitivity, and why it is the usual outcome

Contrast sensitivity is the ability to distinguish an object from a background of similar brightness. It is measured with patterns of light and dark bars at varying contrast rather than with letters, and it captures something the chart does not.

Real seeing is mostly low-contrast. A kerb at dusk, a face in a dim room, a grey road in fog, a document on a slightly glaring screen. Two people with identical acuity can have quite different experiences of all four, and the difference is contrast sensitivity.

The CREST trial made it the primary outcome in people free of retinal disease and found it improved with carotenoid supplementation over twelve months. A second trial measured contrast sensitivity and lateral inhibition and found the same direction. A 2020 randomised trial measured pigment density and contrast sensitivity in the same study and found them moving together.

That is a coherent picture: the pigment layer thickens, and the thing the pigment layer should help with improves.

Five outcomes, five different questions. A trial that moved the third and a trial that moved the fifth have almost nothing to say to each other.

Pigment density: the most direct measure there is

Macular pigment optical density is the closest thing this field has to a direct read on whether a supplement did what it was supposed to do.

It is measured without anything entering the eye, usually with a flicker photometry device in an optometrist's consulting room. It is not a vision test and it is not a diagnosis. It measures how dense the yellow layer is, which is exactly what a carotenoid supplement is trying to change.

Nearly every serious trial in this field reports it, and the reason is practical: it moves before anything functional does. A trial can show that the intervention reached the target tissue months before it can show that the reader's experience changed. That is also why pigment density and functional outcomes get conflated in marketing copy, and they are not the same claim.

The column marketing copy leaves out

The single most useful habit in reading any trial in this field is to look at who was in it before looking at what was found.

The population column is the one to read first. It decides who a finding can be applied to, and it is the column marketing copy omits.

The difference between the first two rows of that table is the difference between two entirely separate claims. AREDS2 enrolled people with existing disease and asked whether it progressed more slowly. CREST enrolled people without disease and asked whether their vision worked better. Both are real findings and neither implies the other.

A head-to-head trial is a third shape again: it compared formulations against each other in people with non-advanced disease, which answers a question a buyer choosing between two bottles might actually have, and which almost no marketing copy cites because the answer is undramatic.

The AREDS2 secondary analyses are where the lutein and zeaxanthin case is strongest, and they are secondary analyses, which is a phrase worth understanding: the comparison was not the trial's pre-specified primary question, so it carries less weight than a primary result would.

What you can and cannot measure at home

None of the instruments above is available to a person in their kitchen, which raises a fair question: what should somebody actually track?

• Glare recovery, roughly. Count the seconds it takes for vision to feel normal after oncoming headlights on the same stretch of road. Crude, repeatable, and pointed at the right thing.
• End-of-day comfort. Score your eyes out of five at a fixed time after a screen day. Subjective, and subjective measures are what two of the bilberry and astaxanthin trials used.
• Low-contrast reading. Whether a dim menu or a grey-on-white interface is easier or harder than it was.
• Not the chart. Acuity is stable and will not move, and watching it not move is how people conclude too early.
• Not a day-to-day comparison. All of the above vary with sleep, screen hours and light. Compare month to month.

What this means for judging Visivra

Three things follow, and they are the practical point of the whole article.

First, the outcome to watch is contrast and glare rather than sharpness. That is what the trials measured in healthy eyes and it is what the benefits page says the label's clarity claim actually points at.

Second, the timescale is months. Every trial in the table above ran for months, and the results timeline page sets out what is fair to expect at each stage.

Third, none of the trials cited here is a claim about this capsule. They used stated amounts and the Visivra label gives none, which is why the ingredients page prints the trial amounts beside an empty column rather than beside a figure.

The bottom line

Eye trials in this field measure contrast sensitivity, pigment density and, in the disease population, progression. They rarely measure acuity, because acuity is not what a carotenoid changes.

Read the population before the result. A finding in people with existing macular degeneration does not transfer to a healthy adult, and a finding about pigment density is not yet a finding about seeing.

And at home, pick one crude measurement pointed at glare or comfort, write it down, and look at it at day thirty, sixty and ninety. That is a test. Squinting at a letter chart in week two is not.

References